We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.69%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$714M
AUM Growth
-$199M
Cap. Flow
+$8.81M
Cap. Flow %
1.23%
Top 10 Hldgs %
30.92%
Holding
97
New
3
Increased
39
Reduced
32
Closed
12

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$10.8M
2
ABBV icon
AbbVie
ABBV
+$10.2M
3
CVS icon
CVS Health
CVS
+$8M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.61M
5
UNH icon
UnitedHealth
UNH
+$6.05M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$10.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.1M
4
HUM icon
Humana
HUM
+$7.42M
5
BDX icon
Becton Dickinson
BDX
+$5.06M

Sector Composition

Rank Sector Weight
1 Healthcare 96.22%
2 Energy 0.06%
3 Technology 0.03%
4 Financials 0.02%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
51
Thermo Fisher Scientific
TMO
$222B
$5.39M 0.75%
+19,000
New +$5.99M
ADVM
52
DELISTED
Adverum Biotechnologies
ADVM
$5.37M 0.75%
55,000
-10,000
-15% -$1.17M
GKOS icon
53
Glaukos
GKOS
$10.7B
$5.09M 0.71%
165,000
-70,000
-30% -$3.59M
BHVN
54
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.76M 0.67%
140,000
+15,000
+12% +$686K
SGMO
55
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.46M 0.62%
700,000
– –
AGIO icon
56
Agios Pharmaceuticals
AGIO
$2B
$3.9M 0.55%
110,000
-50,000
-31% -$2.31M
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
$3.83M 0.54%
295,000
+125,000
+74% +$2.23M
INCY icon
58
Incyte
INCY
$24.6B
$3.66M 0.51%
50,000
-15,000
-23% -$1.13M
DVAX
59
DELISTED
Dynavax Technologies
DVAX
$3.53M 0.49%
1,000,000
-80,000
-7% -$371K
MGTX icon
60
MeiraGTx Holdings
MGTX
$1.21B
$3.31M 0.46%
246,307
+55,007
+29% +$929K
MNTA
61
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.3M 0.46%
121,400
-56,673
-32% -$1.58M
RVNC
62
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.26M 0.46%
220,000
-30,000
-12% -$621K
BDX icon
63
Becton Dickinson
BDX
$49.2B
$3.22M 0.45%
14,350
-20,500
-59% -$5.06M
STML
64
DELISTED
Stemline Therapeutics, Inc.
STML
$3.15M 0.44%
650,000
-110,181
-14% -$714K
QURE icon
65
uniQure
QURE
$3.14B
$3.12M 0.44%
65,798
+5,798
+10% +$333K
BLUE
66
DELISTED
bluebird bio
BLUE
$3.08M 0.43%
5,172
+772
+18% +$752K
RARE icon
67
Ultragenyx Pharmaceutical
RARE
$2.65B
$3.04M 0.43%
+68,524
New +$3.56M
GTHX
68
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.76M 0.39%
250,172
-13,228
-5% -$247K
RIGL icon
69
Rigel Pharmaceuticals
RIGL
$775M
$2.71M 0.38%
173,618
-16,382
-9% -$349K
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
$2.68M 0.38%
100,000
+20,000
+25% +$710K
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.52M 0.35%
40,000
– –
ONC
72
BeOne Medicines Ltd
ONC
$40.9B
$2.46M 0.34%
20,000
– –
AIMT
73
DELISTED
Aimmune Therapeutics
AIMT
$2.38M 0.33%
165,000
+15,000
+10% +$383K
AMRN
74
Amarin Corp
AMRN
$299M
$2.2M 0.31%
27,500
+7,500
+38% +$2.49M
VRAY
75
DELISTED
ViewRay, Inc.
VRAY
$2.13M 0.3%
850,000
+100,000
+13% +$283K
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rhenman & Partners Asset Management held 97 positions worth $714M, down 22% from $913M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2020 filing shows 3 new, 39 increased, 32 reduced and 12 closed positions. Its largest new stake was Zimmer Biomet: 82,400 shares worth $8.09M. The largest sale was Dermira, Inc., an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Energy and Technology.

  • Rhenman & Partners Asset Management's largest Q1 2020 buy was Zimmer Biomet: 82,400 shares worth $8.09M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q1 2020, an estimated $10.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $10.3M.
  • Rhenman & Partners Asset Management fully exited Dermira, Inc. in Q1 2020, selling an estimated $12.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $714M portfolio in Q1 2020.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 12 in Q1 2020.
  • Rhenman & Partners Asset Management's portfolio value fell 22% quarter-over-quarter to $714M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2020, filed 16 Apr 2020.